Treatment with R-bendamustine followed by Y-90 ibritumomab tiuxetan for relapsed/refractory low-grade B-cell lymphoma

被引：0
|
作者：
Nikkuni, Koji [1 ]
Abe, Takashi [1 ]
Takai, Kazue [1 ]
机构：
[1] Niigata City Gen Hosp, Niigata, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O1-13-5
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma
    Tetsuo Hasegawa
    Yoshinobu Aisa
    Kengo Shimazaki
    Tomonori Nakazato
    Annals of Hematology, 2015, 94 : 515 - 517
  • [32] Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma
    Hasegawa, Tetsuo
    Aisa, Yoshinobu
    Shimazaki, Kengo
    Nakazato, Tomonori
    ANNALS OF HEMATOLOGY, 2015, 94 (03) : 515 - 517
  • [33] A phase ii study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL)
    Younes, A
    Rodriguez, M
    Pro, B
    McLaughlin, P
    Romaguera, J
    Hagemeister, F
    Wang, M
    ANNALS OF ONCOLOGY, 2005, 16 : 96 - 96
  • [34] A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL).
    Oki, Y
    Pro, B
    Delpassand, E
    Ballaster, V
    McLaughlin, P
    Romaguera, J
    Wang, M
    Hagemeister, FB
    Younes, A
    BLOOD, 2004, 104 (11) : 720A - 720A
  • [35] Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab
    A J Davies
    Oncogene, 2007, 26 : 3614 - 3628
  • [36] Radioimmunotherapy for B-cell lymphoma:: Y90 ibritumomab tiuxetan and I131 tositumomab
    Davies, A. J.
    ONCOGENE, 2007, 26 (25) : 3614 - 3628
  • [37] Activity of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL).
    Younes, A
    Pro, B
    Rodriguez, MA
    Romaguera, JE
    McLaughlin, P
    Wang, M
    Hagemeister, FB
    Dang, NH
    Neelapu, S
    Podoloff, D
    BLOOD, 2005, 106 (11) : 689A - 690A
  • [38] Ibritumomab tiuxetan plus BEAM in refractory diffuse large B-cell lymphoma
    Prochazka, Vit
    Hlusi, Antonin
    HAEMATOLOGICA, 2014, 99 (07)
  • [39] Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (90Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma
    Watanabe, T
    Terui, S
    Itoh, K
    Terauchi, T
    Igarashi, T
    Usubuchi, N
    Nakata, M
    Nawano, S
    Sekiguchi, N
    Kusumoto, S
    Tanimoto, K
    Kobayashi, Y
    Endo, K
    Seriu, T
    Hayashi, M
    Tobinai, K
    CANCER SCIENCE, 2005, 96 (12): : 903 - 910
  • [40] Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin®) is a safe and effective treatment option for older patients with relapsed or refractory low-grade non-Hodgkin's lymphoma (NHL)
    Meredith, R
    Schilder, RJ
    Emmanouilides, C
    Vo, K
    Witzig, TE
    Flinn, IW
    Darif, M
    Gordon, LI
    Molina, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S421 - S421
12345